share_log

bluebird bio | DEFA14A: Others

bluebird bio | DEFA14A: Others

bluebird bio | DEFA14A：其他
美股SEC公告 ·  10/15 08:04

Moomoo AI 已提取核心信息

bluebird bio, Inc. has filed supplemental disclosure with the SEC, amending its definitive proxy statement ahead of the annual meeting of stockholders scheduled for November 6, 2024. The company clarified who would bear the costs of soliciting proxies, stating that it would cover these expenses, primarily through mail and Internet, with additional outreach by employees and third-party firm Innisfree M&A Incorporated, for a fee not exceeding $30,000 plus expenses. Furthermore, bluebird bio addressed its non-compliance with Nasdaq's Minimum Bid Price Requirement, revealing that its stock closed below the $1.00 threshold for 32 consecutive business days. The company received a notice from Nasdaq on September 30, 2024, and has until March 31, 2025, to meet the requirement or face potential delisting. The company may seek an additional compliance period by transferring to the Nasdaq Capital Market, but there is no assurance of regaining compliance or maintaining other listing requirements.
bluebird bio, Inc. has filed supplemental disclosure with the SEC, amending its definitive proxy statement ahead of the annual meeting of stockholders scheduled for November 6, 2024. The company clarified who would bear the costs of soliciting proxies, stating that it would cover these expenses, primarily through mail and Internet, with additional outreach by employees and third-party firm Innisfree M&A Incorporated, for a fee not exceeding $30,000 plus expenses. Furthermore, bluebird bio addressed its non-compliance with Nasdaq's Minimum Bid Price Requirement, revealing that its stock closed below the $1.00 threshold for 32 consecutive business days. The company received a notice from Nasdaq on September 30, 2024, and has until March 31, 2025, to meet the requirement or face potential delisting. The company may seek an additional compliance period by transferring to the Nasdaq Capital Market, but there is no assurance of regaining compliance or maintaining other listing requirements.
bluebird bio公司已向美国证券交易委员会提交了补充披露，修订了定期股东大会计划于2024年11月6日召开之前的定期代理声明。公司澄清了谁将承担代理征求成本，并声明将主要通过邮件和互联网以及员工和第三方公司Innisfree M&A Incorporated的额外宣传来支付这些费用，费用不超过30,000美元加上额外费用。此外，bluebird bio也解释了其与纳斯达克最低标的价格要求的不符合，披露其股价连续低于1.00美元的门槛32个交易日。公司于2024年9月30日收到纳斯达克的通知，并须在2025年3月31日之前满足要求，否则可能面临摘牌。公司可以通过转移到纳斯达克资本市场寻求额外的符合期限，但不能保证重新符合或满足其他上市要求。
bluebird bio公司已向美国证券交易委员会提交了补充披露，修订了定期股东大会计划于2024年11月6日召开之前的定期代理声明。公司澄清了谁将承担代理征求成本，并声明将主要通过邮件和互联网以及员工和第三方公司Innisfree M&A Incorporated的额外宣传来支付这些费用，费用不超过30,000美元加上额外费用。此外，bluebird bio也解释了其与纳斯达克最低标的价格要求的不符合，披露其股价连续低于1.00美元的门槛32个交易日。公司于2024年9月30日收到纳斯达克的通知，并须在2025年3月31日之前满足要求，否则可能面临摘牌。公司可以通过转移到纳斯达克资本市场寻求额外的符合期限，但不能保证重新符合或满足其他上市要求。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间